Reul R, Kádár J, Bodó I, Gergely P
Second Department of Medicine, Semmelweis University Medical School, Budapest, Hungary.
Acta Med Hung. 1992;49(3-4):201-5.
A one-year study was conducted to evaluate the clinical significance of anticardiolipin antibody (ACA) whether it was a reliable predictor for thromboembolic events and related diseases in systemic lupus erythematosus (SLE) patients. The correlation between ACA and anti-ds-DNA antibodies and disease activity was also studied. Of particular importance was the question if any association could be found between ACA positivity and renal disorders in SLE patients. One hundred and eighty-seven serum samples from 88 SLE patients were assayed for ACA. Clinical records of these patients were reviewed for a history of thromboembolic events, related diseases and renal disorders, 80.7% of the 88 SLE patients were positive for ACA. The incidence of thrombosis and related diseases within this group was 35.1%. Since the correlation was not significant, it does not seem to be advisable to use elevated ACA values as predictive for thromboembolic events and related diseases. On the other hand, an apparent association between ACA levels, anti-DNA antibody levels and disease activity was found.
进行了一项为期一年的研究，以评估抗心磷脂抗体（ACA）的临床意义，即它是否是系统性红斑狼疮（SLE）患者血栓栓塞事件及相关疾病的可靠预测指标。还研究了ACA与抗双链DNA抗体及疾病活动度之间的相关性。特别重要的问题是，能否在SLE患者中发现ACA阳性与肾脏疾病之间存在任何关联。对88例SLE患者的187份血清样本进行了ACA检测。查阅了这些患者的临床记录，以了解血栓栓塞事件、相关疾病和肾脏疾病的病史，88例SLE患者中有80.7%的ACA呈阳性。该组中血栓形成和相关疾病的发生率为35.1%。由于相关性不显著，将升高的ACA值用作血栓栓塞事件及相关疾病的预测指标似乎并不可取。另一方面，发现ACA水平、抗DNA抗体水平与疾病活动度之间存在明显关联。
